PALVELLA THERAPEUTICS INC (PVLA) Stock Price, Forecast & Analysis
USA - NASDAQ:PVLA - US6979471090 - Common Stock
PVLA Key Statistics, Chart & Performance
The current stock price of PVLA is 83.72 USD. In the past month the price increased by 14.45%.
PVLA Latest News, Press Relases and Analysis
PVLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About PVLA
Company Profile
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Company Info
PALVELLA THERAPEUTICS INC
353 W. Lancaster Avenue, Suite 200
Wayne PENNSYLVANIA US
Employees: 14
Phone: 14842531461
PALVELLA THERAPEUTICS INC / PVLA FAQ
What does PALVELLA THERAPEUTICS INC do?
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
What is the stock price of PALVELLA THERAPEUTICS INC today?
The current stock price of PVLA is 83.72 USD. The price increased by 4% in the last trading session.
Does PALVELLA THERAPEUTICS INC pay dividends?
PVLA does not pay a dividend.
How is the ChartMill rating for PALVELLA THERAPEUTICS INC?
PVLA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about PALVELLA THERAPEUTICS INC (PVLA) stock?
19 analysts have analysed PVLA and the average price target is 82.85 USD. This implies a price decrease of -1.03% is expected in the next year compared to the current price of 83.72.
Can you provide the market cap for PALVELLA THERAPEUTICS INC?
PALVELLA THERAPEUTICS INC (PVLA) has a market capitalization of 925.94M USD. This makes PVLA a Small Cap stock.
What is the Short Interest ratio of PALVELLA THERAPEUTICS INC (PVLA) stock?
The outstanding short interest for PALVELLA THERAPEUTICS INC (PVLA) is 16.19% of its float.
PVLA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PVLA.
PVLA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PVLA. PVLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PVLA Financial Highlights
Over the last trailing twelve months PVLA reported a non-GAAP Earnings per Share(EPS) of -5.35. The EPS increased by 34.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.07% | ||
| ROE | -38.7% | ||
| Debt/Equity | 0.24 |
PVLA Forecast & Estimates
19 analysts have analysed PVLA and the average price target is 82.85 USD. This implies a price decrease of -1.03% is expected in the next year compared to the current price of 83.72.
For the next year, analysts expect an EPS growth of 99.01% and a revenue growth 20.37% for PVLA